In addition to SGLT2 inhibitors and GLP-1 receptor agonists, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated significant cardiovascular and kidney-protective effects in people with type 2 diabetes mellitus and CKD or HF [129-132]
Cochrane Database Syst Rev issue 1, CD013823.Google Scholar et al
R.TavaresR.et al (2005)
While all forms of weight loss, including treatment with GLP-1 medications, results in some degree of lean body mass and skeletal muscle loss, it's crucial to understand the broader context
Peptides are highly targeted, the right choice depends on whether your goal is tissue repair, GH optimization, libido, cognition, or weight management
Tirzepatide currently has the advantage of regulatory approval and extensive clinical data, whereas mazdutide remains under investigation, with ongoing trials needed to confirm its long-term safety and effectiveness